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Human genetic studies have revealed an association
between GTP cyclohydrolase 1 polymorphisms,
which decrease tetrahydrobiopterin (BH4) levels,
and reduced pain in patients. We now show that
excessive BH4 is produced in mice by both axotom-
ized sensory neurons and macrophages infiltrating
damaged nerves and inflamed tissue. Constitutive
BH4 overproduction in sensory neurons increases
pain sensitivity, whereas blocking BH4 production
only in these cells reduces nerve injury-induced hy-
persensitivity without affecting nociceptive pain. To
minimize risk of side effects, we targeted sepiapterin
reductase (SPR), whose blockade allows minimal
BH4 production through the BH4 salvage pathways.
Using a structure-based design, we developed
a potent SPR inhibitor and show that it reduces
pain hypersensitivity effectively with a concomitant
decrease in BH4 levels in target tissues, acting both
on sensory neurons and macrophages, with no
development of tolerance or adverse effects. Finally,
we demonstrate that sepiapterin accumulation is a
sensitive biomarker for SPR inhibition in vivo.
INTRODUCTION
Most putative analgesic compounds tested over the last decade
have failed in phase II trials due to lack of efficacy, even thoughthey have robust preclinical activity (Arrowsmith andMiller, 2013;
Woolf, 2010). One strategy to improve chances of translational
success is to select a target or pathway for drug development
with strong human genetic support. For example, patients car-
rying rare Mendelian recessive loss-of-function mutations for
the sodium channel NaV1.7 are completely indifferent to pain
(Dib-Hajj et al., 2013), making this channel a potential target for
eliminating acute pain sensitivity (Lee et al., 2014). Although
informative for nociceptive pain, rare Mendelian conditions
with large phenotypes may not be effective for selecting drug-
gable targets for chronic pathological conditions, such as neuro-
pathic pain and chronic inflammatory disease, as the chance of
associating a diminished disease phenotype with a rare poly-
morphism is extremely low if the phenotype only manifests in
the disease state, such as after a nerve lesion (Bennett and
Woods, 2014; Costigan et al., 2012). An alternative approach is
to identify relatively common genetic polymorphisms with
smaller effect sizes on pain outcome in disease conditions,
ideally with no effect on nociceptive pain, as these may reveal
potential ways to alter specific molecular mechanisms respon-
sible for pathological pain while leaving the protective aspects
of acute pain intact.
SNP association studies carried out in 12 independent cohorts
of patients have associated several polymorphisms within
or close to the gene for GTP cyclohydroxylase 1 enzyme
(GTPCH1; hereafter named GCH1) with reduced clinical and
experimental pain sensitivity (Belfer et al., 2014; Kim et al.,
2013; Latremoliere and Costigan, 2011). GCH1 catalyzes the
initial and rate-limiting step in the synthetic pathway of the
pteridin (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4). BH4
is an essential cofactor for aromatic amino acid hydroxylases,Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc. 1393
nitric oxide synthases (NOSs), and alkylglycerol monooxyge-
nase, making it indispensable for synthesis of serotonin,
epinephrine, norepinephrine, dopamine, nitric oxide, and meta-
bolism of glycerolethers (Werner et al., 2011). That particular
polymorphisms in GCH1 are associated with less clinical pain
without CNS adverse effects or disruption of nociception repre-
sents a functional outcome that would be highly desirable to
replicate pharmacologically.
A general challenge of human genetic association studies is
how to reverse engineer the discovery of a polymorphic gene
associated with a desirable clinical outcome into a druggable
target supported by robust mechanistic validation in model
organisms. Expression and functional profiling in rodents has
shown that enhanced GCH1 transcription and activity in injured
sensory neurons lead to increased BH4 levels, which results in
greater pain hypersensitivity, and conversely that inhibiting this
enzyme’s function reduces pain (Kim et al., 2009; Nasser et al.,
2013; Tegeder et al., 2006). Crucial questions remain, however;
where and how do excess BH4 levels contribute to neuropathic
and inflammatory pain and, from a translational perspective, can
disruption of the synthesis of this critical cofactor constitute a
viable analgesic drug development strategy without generating
unacceptable side effects?
To address these issues, we set out to determine where
anatomically the BH4 pathway regulates the pain phenotype
in vivo and the functional consequences of increased or
decreased BH4 levels in sensory neurons. Finally, we pharmaco-
logically targeted the terminal BH4 synthetic enzyme sepiapterin
reductase (SPR) as a way of reducing pathologically elevated
BH4. These murine studies define and validate a molecular
pathway (BH4 synthesis) that contributes to pain hypersensitivity
following nerve injury and inflammation and its locus of activation
(injured neurons and macrophages), and from this reveal a spe-
cific target (SPR) for reducing elevated BH4 synthesis while mini-
mizing adverse effect liability.
RESULTS
Cellular Localization of GCH1 in Injured
Sensory Neurons
To identify cells that produceBH4after peripheral nerve injury,we
used bacterial artificial chromosome transgenic reporter mice in
which GFP is expressed under control of the endogenous Gch1
promoter, asGch1 expression is tightly correlated with BH4 pro-
duction (Tatham et al., 2009). In naive reporter mice, the GFP
signal was below detection levels in sciatic nerves and dorsal
root ganglia (DRGs), indicating low basal Gch1 transcriptional
activity (Figures 1A and 1E). Seven days after injury to the sciatic
nerve, numerous GFP-positive cells were detected in the prox-
imal segment of the damaged nerve (Figure 1B). Increase in
GCH1 levels was confirmed by western blot and enzyme activity
(Figure 1C). Costaining with CD68 revealed that a large propor-
tion of the GFP-positive cells were macrophages (Figure 1D).
In lumbar level (L)3 and L4 DRGs ipsilateral to a sciatic nerve
injury a week before, neuronal Gch1 transcriptional activity also
increased, as detected by increased GFP signal and enzyme
activity (Figure 1F). A soma size distribution analysis showed a
mixed population of small- (<30 mm), medium- (30–40 mm), and1394 Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc.large- (>40 mm) diameter GFP+ DRG neurons after injury (Fig-
ure 1G). Costaining with specific molecular markers revealed
that only axotomized neurons (ATF3+) showed elevated expres-
sion of Gch1 after the nerve injury (Figure 1H), and that these
included myelinated (NF200+) and unmyelinated (NF200) neu-
rons. Among the unmyelinated neuronal population, both pepti-
dergic (CGRP+, SP+, and TRPV1+) and nonpeptidergic (IB4+)
neurons expressedGch1 (Figures 1I–1L). Together, these results
indicate that after a peripheral nerve injury, Gch1 transcription is
upregulated both in macrophages in the nerve proximal to the
injury and in injured neurons, including all major sensory neuron
classes. The proportion of neurons expressing Gch1 21 days
after spared nerve injury (SNI) was similar to that found at
7 days (Figure S1A), indicating that elevated transcription
persists for some time after injury.
Regulation of BH4 Synthesis, Recycling, and Salvage
Pathways after Peripheral Nerve Injury
Cellular levels of BH4 are determined by the combined action of
de novo synthesis, recycling, and salvage pathways (Figure 1M).
We therefore measured changes following sciatic nerve injury
in the expression of transcripts for enzymes in all these three
pathways in the nerve and DRG. In addition to Gch1, which
was upregulated in injured nerves and DRGs at each time point
tested, we also found upregulation of carbonyl reductase 2
(Cbr2) in the two tissues. Dihydrofolate reductase (Dhfr), a
salvage pathway enzyme, was transiently upregulated in the
DRG, but exhibited a more sustained increase in the injured
nerve. None of the enzymes related to BH4 production changed
their transcript profiles in the dorsal horn of the spinal cord
(Figure 1N). Collectively, the increase in the expression of the
transcripts for these enzymes correlates with an elevation in
biopterin levels (an oxidized biomarker of BH4) in the DRGs
and in proximal injured nerves (Figure 1O). These results indicate
that several enzymes involved in BH4 production are upregu-
lated in the mouse after peripheral nerve injury, and that BH4
levels are increased not only in the DRGs, as previously reported
in the rat (Tegeder et al., 2006), but also in infiltrating immune
cells of the injured sciatic nerve.
Forced Expression of GCH1 in Sensory Neurons
Increases Pain Sensitivity in Naive Mice
To test whether increasing BH4 levels specifically in sensory
neurons can enhance pain sensitivity in naive animals, we
generated a Cre-recombinase-dependent GCH1 overexpressor
mouse line. These animals contain a transgene that expresses
the human GCH1 gene tagged with an influenza hemagglutinin
(HA) tag under the human cytomegalovirus early enhancer/
chicken b-actin (CAG) promoter in cells (Figure 2A). We crossed
these animals with a sensory neuron-specific Advillin-Cre line
(Hasegawa et al., 2007) to generate GCH1-HA-overexpressing
(OE) mice in all sensory neurons, as revealed by immunostaining
of the HA tag and the size distribution of HA-positive cells (Fig-
ures 2A and 2B). Overexpression of the transgene was also
observed by western blot using antibodies directed against
GCH1 or the HA tag in the sciatic nerve and DRG (Figure 2C).
Measurement of enzyme activity and biopterin levels in the
DRGs of these mice showed that overexpression of GCH1 led
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Figure 1. BH4 Synthesis after Nerve Injury
(A and B) eGFP staining in naive sciatic nerve (A) and proximal to nerve lesion 7 days after SNI (B). The scale bars represent 200 mm.
(C) GCH1 protein (n = 9) and GCH1 activity in sciatic nerve (SN) 7 days after SNI (n = 6).
(D) Costaining of GFP with CD68 in SN 7 days after SNI. Arrows indicate double-positive cells. The scale bar represents 50 mm.
(E and F) eGFP staining in naive DRG (E) and 7 days after SNI (F). The scale bars represent 50 mm.
(G) Size distribution of GFP-positive neuron diameters (n = 1,493 neurons) and GCH1 activity (n = 6) in DRG 7 days after SNI. 1 unit (U) = 1 mmol 7,8-dihy-
droneopterin triphosphate formed per min.
(H–L) Costaining of eGFPwith ATF3 (H), NF200 (I), TRPV1 (J), CGRP (K), and IB4 (L) in DRG 7 days after SNI. Arrows indicate double-positive cells. The scale bars
represent 50 mm.
(M) Metabolic pathways (de novo, salvage, and recycling) involved in BH4 production.
(N) Quantitative (Q-)PCR time course of enzymes involved in BH4 production in SN,DRG, and dorsal horn after SNI. Numbers indicate fold changes (n = 3mice per
sample; three samples per time point). Bold characters are significant compared to baseline (BSL). Blue indicates no change; red indicates an increase.
(O) Biopterin concentration in SN and DRG 7 days after SNI (n = 40–50).
Mean ± SEM. *p < 0.05; two-tailed unpaired Student’s t test versus naive condition (C, G, and O); one-way ANOVA followed by Dunnett’s post hoc test (N). Ptps,
pyruvoyl-tetrahydrobiopterin synthase; Akr1b3/e1, aldoketo reductase (AR) family 1, member b3/e1; Crb1–4, carbonyl reductase 1–4; Qdpr, quinoid dihy-
dropteridine reductase; PCBD, pterin-4a-carbinolamine dehydratase. See also Figure S1.
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Figure 2. BH4 Overexpression in Sensory Neurons Increases Pain Sensitivity
(A and H) Genetic construct to overexpressGCH1-HA (top); costaining of HA (green) with NF200 (red) in DRG ofAdvillin-GCH1-HAOE (A-GOE) (A) andNa(v)1.8Tg-
GCH1-HA OE (N-GOE) (H) mice.
(B and I) Distribution of HA-positive and -negative neurons in A-GOE (B) and N-GOE (I) mice (n = 235 and 165 neurons for B and I, respectively).
(C and J) Detection of transgene by western blot using antibodies directed against GCH1 or HA in SN and DRG of A-GOE (C) and N-GOE (J) mice (n = 3 mice per
sample, three samples per condition).
(D and K) GCH1 activity in DRG of A-GOE (D) and N-GOE (K) mice (n = 3–5; 1 U = 1 mmol 7,8-dihydroneopterin triphosphate formed per min).
(E and L) Biopterin concentration in DRG of A-GOE (E) and N-GOE (L) mice (n = 3–6).
(F and M) Nocifensive response after intraplantar injection of 1 mg of capsaicin into A-GOE (F) and N-GOE (M) mice (n = 7–10).
(G and N) Radiant heat withdrawal latencies in A-GOE (G) and N-GOE (N) mice (n = 8–12).
(O) Radiant heat withdrawal latencies in A-GOE mice and littermates after injection of L-NAME (50 mg/kg i.p.; n = 6–9).
(P) Thermal place preference of N-GOE mice and littermates on a 4C–55C thermal gradient (n = 7–9).
(Q) Costaining of HA (green) with NF200 (red) in DRG of Brn3a-GCH1-HA OE mice 1 week after tamoxifen treatment.
(R) Contact heat withdrawal latencies at 52C in Brn3a-GCH1-HA OE mice before and after tamoxifen treatment (n = 6–10).
Mean ± SEM. *p < 0.05; two-tailed unpaired Student’s t test compared with littermates (D–G, K–N, and R). *p < 0.05; two-way ANOVA followed by Bonferroni’s
post hoc test compared with littermates treated with L-NAME (O). xp < 0.05; two-way ANOVA followed by Bonferroni’s post hoc test compared with vehicle-
treated littermates (O). The scale bars represent 50 mm. See also Figure S2.to increased GCH1 activity and BH4 overproduction (Figures 2D
and 2E).
The genetically engineered constitutive overexpression of
BH4 selectively in sensory neurons caused increased nocifen-
sive responses upon intraplantar injection of the TRPV1 agonist
capsaicin (Figure 2F) and a heightened sensitivity to radiant1396 Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc.(Figure 2G) and contact heat (Figure S2A), whereas mechanical
sensitivity, tested by von Frey filaments and calibrated forceps,
did not differ from littermates (Figures S2B and S2C). These re-
sults suggest that BH4 overexpression in naive animals mainly
affects the sensitivity of C fiber nociceptor neurons responsive
to heat and chemical stimuli. To confirm this, we crossed the
conditional GCH1-HA OE line with Na(v)1.8Tg-Cre transgenic
animals, where Cre expression is restricted to small-diameter
neurons (Agarwal et al., 2004). As expected, GCH1-HA was
expressed only in small sensory neurons (Figures 2H and 2I).
Protein levels of GCH1-HA, enzyme activity, and biopterin levels
were significantly increased in the Na(v)1.8Tg-GCH1-HA OE ani-
mals compared to their littermates, both in the sciatic nerve and
DRG (Figures 2J–2L). The nociceptive pain profile of these mice
fully phenocopied that of theAdvillin-GCH1-HAOE animals, indi-
cating that restricting overexpression of BH4 to small-caliber
fibers is sufficient to cause a hypersensitivity to noxious heat
and capsaicin (Figures 2M and 2N; Figures S2D–S2F). Because
BH4 sensitizes TRPV1 channels through nitrosylation in vitro
(Miyamoto et al., 2009), we administered L-NG-nitroarginine
methyl ester (L-NAME; 50 mg/kg intraperitoneally [i.p.], a
dose that fully blocks NOS activity; Moore et al., 1993) to the
Advillin-GCH1-HA OE mice. This treatment normalized the
radiant heat responses to levels similar to littermates (Figure 2O).
These results imply that BH4 is acting in a cell-autonomous
fashion—changing neural function where its levels are
increased. To test whether BH4 overexpression affected the
detection of nonnoxious temperatures, we used thermal gradient
paradigms (Moqrich et al., 2005). Na(v)1.8Tg-GCH1-HA overex-
pressor mice and their littermates both settled at 32C within
an hour, indicating no effect of BH4 overexpression on innoc-
uous thermodetection (Figure 2P; Figure S2G). Finally, we also
tested whether a short-term exposure to increased GCH1 activ-
ity in neurons was sufficient to heighten heat pain sensitivity. To
evaluate this, we used an inducible sensory-neuron-specific
Brn3a-CreERT2 mouse (O’Donovan et al., 2014). Tamoxifen
administration (1 mg per mouse i.p. for 5 days) induced GCH1-
HA in all sensory neurons observed 1 week after the end of
treatment (Figure 2Q), and the mice developed hypersensitivity
to contact heat (Figure 2R) but not to von Frey filaments
(Figure S2H).
We conclude that an increase in BH4 synthesis in uninjured
DRG neurons is sufficient to produce heightened heat pain
sensitivity, and that this occurs in this context through increased
NO synthesis.
Loss of GCH1 in Sensory Neurons Attenuates
Neuropathic Pain
Next, we tested whether specifically preventing BH4 upregu-
lation in sensory neurons after a nerve injury diminished the
neuropathic pain phenotype. Because Gch1 is upregulated in
myelinated and unmyelinated neurons after peripheral nerve
injury, we crossed the Advillin-Cre driver line with mice in which
exons 2 and 3 of the Gch1 gene are flanked by flox sequences
(Chuaiphichai et al., 2014). These exons code the active site of
the enzyme, and their excision by Cre led to a large decrease
of enzymatic activity in DRG tissue and cultures of primary sen-
sory neurons (Figure 3A). GCH1 activity was also reduced in the
intact sciatic nerve (Figure 3B), implying that GCH1 present in
naive animals has a predominant sensory neuronal origin and
is likely axonally transported, as reported in the brain (Levine
et al., 1981). No differences were observed in the responses to
radiant or contact heat, capsaicin, von Frey filaments, or cali-
brated forceps (Figures 3C–3G) in naive Advillin-Gch1 knockout(KO) animals when compared to their littermates, indicating that
active BH4 synthesis in sensory neurons is not necessary for
nociceptive pain.
After peripheral nerve injury (SNI model), Advillin-Gch1 KO
mice did not display the increase in biopterin levels in DRGs
observed in littermates after such lesions (Figure 3H) and ex-
hibited significantly reduced mechanical sensitivity (higher
thresholds) throughout the 3 weeks of testing (Figure 3I), but
showed no difference in the response to cold produced by
acetone evaporation (Figure S3A). A similar reduced mechanical
hypersensitivity was also observed when Advillin-Gch1 KOmice
were subjected to the chronic constriction injury (CCI) model
of peripheral neuropathic pain (Figure S3B). Elevated Gch1
mRNA was still evident in the injured sciatic nerve of the
Advillin-Gch1 KO SNI mice, showing that in the damaged nerve,
Gch1 synthesis is largely nonneuronal in origin (Figure 3J), likely
mainly macrophages (Figures 1B and 1D), and this was sup-
ported by increased BH4 levels in the injured nerve of both WT
and Advillin-Gch1 KO mice (Figure 3K), which has, therefore,
two sources: injured sensory neurons and infiltrating leukocytes,
with the latter predominant.
To test whether blocking BH4 synthesis in sensory neurons
could alleviate established neuropathic pain-like behaviors, we
used inducible Brn3a-CreERT2 Gch1 floxed mice. Immediately
following nerve injury all mice developed identical levels of
mechanical hypersensitivity, but tamoxifen treatment (1 mg per
mouse i.p. for 5 days starting on day 7) resulted in an increase
in threshold only in the Brn3a-CreERT2 Gch1 KO mice from day
14 until testing ended on day 25 (Figure 3L).
Specific reduction of BH4 production in sensory neurons can
then both prevent and alleviate, to a substantial but incomplete
extent, established nerve injury-induced pain hypersensitivity.
Because we found infiltrating immune cells to be a major source
of BH4 in the damaged nerve after peripheral nerve injury, we
next sought to reduce BH4 production in both cell types by
genetic and pharmacological means, to test whether this could
further reduce neuropathic pain hypersensitivity.
Pharmacological Inhibition of BH4 Synthesis
and Reduced Pain Hypersensitivity
The only known inhibitor of GCH1 is 2,4-diamino-6-hydroxypyri-
midine (half-maximal inhibitory concentration [IC50] 300 mM;
Kolinsky and Gross, 2004), which produces analgesia in rats
(Pickert et al., 2012; Tegeder et al., 2006). GCH1 is the obligate
and rate-limiting step forBH4production and, as a consequence,
its complete inhibition for extended periods would prevent
any new BH4 synthesis, likely precipitating side effects due to
reduced levels of biogenic amines and NO synthesis. Further-
more, the GCH1 complex is not a readily tractable drug target
because of the lack of accessible active sites, which point inward
in a dipentameric barrel-like structure (Nar et al., 1995a, 1995b).
We therefore considered another enzyme within the BH4
synthesis cascade, sepiapterin reductase, the terminal enzyme
in the de novo synthesis pathway, as a potential target for
reducing pathologically elevated BH4 levels. X-ray crystallog-
raphy has revealed a clear pocket for its known inhibitor N-ace-
tylserotonin (NAS; Auerbach et al., 1997; Naylor et al., 2010;
Smith et al., 1992), opening opportunities to look for otherNeuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc. 1397
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Figure 3. Lack of GCH1 in Sensory Neurons Attenuates Neuropathic Pain-like Symptoms
(A) Top: genetic construct used to excise exons 2 and 3 ofGch1 uponCre-recombinase exposure. Bottom: GCH1 activity fromDRG tissue (left) and primary DRG
neuron culture (right) of Advillin-Gch1 KO mice (n = 3–9).
(B) GCH1 activity from sciatic nerves of KO mice (n = 6–9; 1 U = mmol 7,8-dihydroneopterin triphosphate formed per min).
(C and D) Radiant (C) and contact (D) heat withdrawal latencies in KO mice (n = 8–13).
(E) Nocifensive response after intraplantar injection of 1 mg of capsaicin into KO mice (n = 7–8).
(F) Number of withdrawals out of ten von Frey filament applications to plantar surface of hindpaw in KO mice (n = 11).
(G) Calibrated forceps-elicited withdrawal response in KO mice (n = 12).
(H) Biopterin concentration in DRG of naive KO mice and littermates 7 days after SNI (n = 8–9).
(I) Mechanical hypersensitivity in KO mice and their littermates in the SNI model (n = 12–15).
(J) Q-PCR of Gch1 in sciatic nerve and DRG of KO mice or naive 7 days after SNI (n = 2 mice per sample; three samples per condition).
(K) BH4 levels in sciatic nerve of WT and KO mice after SNI (n = 12–14).
(L) Mechanical hypersensitivity in Brn3a-Gch1 KOmice and littermates in the SNI model (n = 8–10). The black bar represents the duration of tamoxifen treatment
(days 8–13).
Mean ± SEM. *p < 0.05; two-tailed unpaired Student’s t test compared with littermates (A, B, and K); two-way ANOVA followed by Bonferroni’s post hoc test
compared with littermates (I and L). xp < 0.05; two-tailed unpaired Student’s t test compared with uninjured condition of the same genotype (H and J). See also
Figure S3.inhibitors. NAS has an IC50 of 50 mM (Chidley et al., 2011)
but is also an intermediate in melatonin production, making
systemic use unfeasible (Tegeder et al., 2006). Recently, sulfa-
salazine (SSZ), a Food and Drug Administration-approved
anti-inflammatory compound, was found in a yeast three-
hybrid screen to inhibit SPR activity through its metabolite
sulfapyridine (IC50 200 mM; Haruki et al., 2013). Given the pro-
duction of excess BH4 in sensory neurons and in infiltrating
macrophages, we decided to test whether this anti-inflamma-
tory agent reduced pain-related hypersensitivity in mice after
SNI. Because intestinal flora metabolizes sulfasalazine into
sulfapyridine (which otherwise has a poor solubility), we admin-
istered sulfasalazine (50 mg/kg) by gavage twice a day for
3 days, beginning 7 days after SNI. With this regime, SSZ
on the third day of administration modestly reduced mecha-
nical hypersensitivity for 2 hr with a maximum effect at 1 hr
(Figure S3C).1398 Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc.The limited bioavailability, low potency, and complex meta-
bolism of SSZ did not allow direct analysis of the relationship
between BH4 levels and reduced pain-like behavior. We there-
fore used structure-based design to produce a more potent
SPR inhibitor, guided by the crystal structure of mouse SPR
in complex with NAS (PDB: 1NAS; Auerbach et al., 1997) and
previous work on this scaffold by Smith et al. (1992), and de-
signed the compound illustrated in Figure 4A, N-(2-(5-hydroxy-
2-methyl-1H-indol-3-yl)ethyl)-2-methoxyacetamide, which we
named SPRi3 as the third SPR inhibitor (after NAS and SSZ).
Compared to NAS, SPRi3 has an additional methyl group at
the 2-position of the indole scaffold to allow for additional
hydrophobic interactions and a methoxyacetyl group instead
of the acetyl group, as it has been shown that the latter modifica-
tion significantly increases the affinity of NAS toward SPR
(Smith et al., 1992). SPRi3 displayed very high binding affinity
to human (h)SPR in a cell-free assay (IC50 74 nM versus 1.9 mM
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Figure 4. Inhibiting BH4 Production by Tar-
geting SPR
(A) Structure of SPRi3 (top) and NAS (bottom).
(B and C) Concentration-response curves of NAS
and SPRi3 binding affinity to SPR tested in vitro by
time-resolved fluorescence resonance energy
transfer assay (TR-FRET) (B) and reduction of
biopterin levels in SK-N-BE(2) neuroblastoma
cells (C); 100% synthesis corresponds to biopterin
levels after 24 hr incubation with vehicle. Top:
calculated IC50.
(D) Sepiapterin reductase activity in DRG neuron
cultures after 24 hr incubation with various doses
of SPRi3 (n = 3–5 samples per condition; 1 U =
mmol sepiapterin consumed per min).
(E) Conformation and interactions of SPRi3 within
the substrate-binding site of hSPR (PDB: 4XWY).
The four hydrogen bonds between SPRi3 and
amino acids of the substrate-binding site are
indicated as yellow dotted lines. Hydrophobic
interactions are observed between the 2-methyl
moiety and Leu219, as well as between the me-
thoxyacetyl group and Met202-Gln203 (image
made with MacPyMOL; http://www.pymol.org).
(F) The surfaces of hSPR, SPRi3, and NADPH are
indicated as blue, purple, and yellow surfaces,
respectively. Shown is a view from the outside
looking into the substrate-binding site. Note that
the 5-hydroxy group is in close contact with the
wall of the binding site.
(G) Plasma levels of SPRi3 in mice after an i.p.
injection of 300mg/kg determined by LC-MS (n = 3
mice per point).
(H) Schematic representation of the enzymatic
cascades that form the salvage pathway. Dark
blue indicates the de novo pathway that forms 6PPH4 (6-pyruvoyl-tetrahydropterin). SPR (light blue) carries out two reactions to produce BH4. When SPR
is absent, 6PPH4 can bemetabolized into BH4 through the sequential actions of AKR1C3/CR and AKR1B1/CR (green) or AKR1B1/CR, CR, and DHFR (red). In the
latter cascade, the metabolite sepiapterin is formed nonenzymatically from 10oxoPH4.
(I) Sepiapterin release after inhibition of SPR activity by SPRi3 in DRG neurons (n = 3 samples per condition). In normal conditions or when the de novo pathway is
promoted by IL-1b, sepiapterin is not detectable. SPR inhibition leads to increased levels of sepiapterin. Ø: not detected.
(J) Correlation between plasma sepiapterin and SPRi3 levels.
Mean ± SD from triplicate experiments (B and C); mean ± SEM otherwise. *p < 0.05; one-way ANOVA followed by Dunnett’s post hoc test compared with no
SPRi3 condition. xp < 0.05; one-tailed Mann-Whitney test compared with no SPRi3 in the presence of IL-1b condition. See also Figure S4.for NAS; Figure 4B) and efficiently reduced biopterin levels in a
cell-based assay (IC50 5.2 mM versus 54 mM for NAS; Figure 4C),
consistent with good cell permeability (Caco-2: Papp A to B:
10.7 3 106 cm,s1; efflux ratio 1.4). SPRi3 also significantly
reduced SPR activity in mouse primary cultures of sensory neu-
rons (IC50 0.45 mM; Figure 4D) without affecting the activity of
GCH1 (Figure S4A).
We then solved the crystal structure of hSPR in complex
with SPRi3 and NADPH (PDB: 4XWY). As observed for NAS,
the 5-hydroxy group of SPRi3 is anchored via hydrogen bonding
to the conserved Asp254 (Figure 4E; Figure S4). The side chain of
SPRi3 penetrates deep into the substrate-binding site, where its
cis-amide bond forms hydrogen bonds with catalytic residues
Ser154 and Tyr167 (Figure 4E). This is in contrast to the structure
of NAS bound to SPR, where no hydrogen bonds between the
amide bond and the active-site residues are formed (Figure S4B).
The methoxyacetyl group of SPRi3 makes extensive hydropho-
bic interactions withMet202 andGln203, and the 2-methyl group
of the indole scaffold makes hydrophobic contacts with residueLeu219. Evidently, SPRi3 fits very well in the substrate-binding
site of hSPR (Figure 4F). In contrast to the structures of sulfa
drugs bound to SPR, there is little direct interaction between
SPRi3 and the cofactor NADPH (Figure S4C). Overall, the struc-
ture of the ternary complex of SPRi3, NADPH, and SPR explains
both the exquisite binding affinity of SPRi3 and why it is a more
potent SPR inhibitor than NAS.When administered tomice i.p. at
300 mg/kg, plasma levels of SPRi3 had a rapid (Tmax 0.11 hr) and
short exposure, an elimination half-life of 3.95 hr (Figure 4G) with
low plasma protein binding (11.6%).
Whereas under normal conditions SPR mediates the conver-
sion of its substrate 6-pyruvoyl-tetrahydropterin to BH4, in the
absence of enzyme activity due, for example, to genetic muta-
tion, low-level production of BH4 can still be achieved through
the salvage pathway in various cell types (Figure 4H; Bonafe´
et al., 2001; Hirakawa et al., 2009; Tho¨ny and Blau, 2006). This
could act to prevent excessive global depletion of basal levels
of BH4 during SPR inhibition. The sequential action of the
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and dihydrofolate reductase (DHFR) involves the nonenzymatic
production of sepiapterin from 20-hydroxy-10-oxopropyltetrahy-
dropterin (10oxoPH4; Figure 4H). Sepiapterin does not normally
accumulate, because SPR reduces 10oxoPH4 into BH4, and
this metabolite is therefore not an endogenous substrate for
this enzyme (Milstien and Kaufman, 1989; Nichol et al., 1983).
Because sepiapterin is chemically stable its accumulation could,
however, represent a biomarker of SPR inhibition, and indeedwe
found that sepiapterin levels increased concomitantly with SPR
inhibition in cultured DRG neurons (Figure 4I). Sepiapterin levels
were undetectable both in normal states and when the de novo
pathway activity was increased by interleukin (IL)-1b, whereas
application of SPRi3 caused a concentration-dependent in-
crease in the metabolite (Figure 4I). When SPRi3 was adminis-
tered in vivo, sepiapterin levels in plasma correlated highly with
those of SPRi3 (r = 0.9166), confirming its utility as a biomarker
for sepiapterin reductase inhibition (Figure 4J). SSZ treatment
also increased plasma levels of sepiapterin (Figure S4D). These
data confirm in vivo target engagement of both SSZ and SPRi3
as SPR inhibitors.
SPRi3 administered at 100, 200, or 300 mg/kg (i.p.) produced
a dose-dependent anti-tactile allodynic effect in mice in the SNI
model of neuropathic pain, with a maximum response 1 hr after
injection (Figure 5A). At this dose, SPRi3 also reduced mechan-
ical allodynia in mice with a different neuropathic pain model,
chronic constriction injury, with a similar time course (Figure 5A).
One hour after injection of the most efficacious dose (300 mg/
kg), SPRi3 was detected in both injured sciatic nerves and
DRGs of SNI mice, and this was associated with a reduction in
SPR activity and an increase in sepiapterin levels, as well as
reduction in BH4 levels in these two tissues (Figures 5B and
5C). Administration of SPRi3 in naive mice did not affect noci-
ceptive pain (Figures S5B–S5D).
To determine whether the anti-allodynic effect of SPRi3 in the
SNI pain model was solely mediated through inhibition of SPR in
sensory neurons, we administered it to Advillin-Gch1 KO mice
after SNI. SPRi3 produced a modest but significant further
anti-allodynic effect for an hour after injection, on top of the
already reduced pain-like sensitivity of these animals (Figure 5D).
These results suggest that systemic SPR inhibition has an action
other than just on sensory neurons, such as on macrophages in
the injured nerve (Figure 1D). To evaluate this, we assessed the
effect of SPR blockade on macrophages in vitro. SPRi3
(50 mM) added to purified peritoneal macrophages activated by
lipopolysaccharide (LPS) (5 mg/ml) for 24 hr or LPS followed by
1 hr ATP (1 mM) prevented NO generation but not proinflamma-
tory cytokine (IL-1b and IL-6) production (Figure 5E; Figure S5E),
indicating action of the inhibitor on specific aspects of this im-
mune cell’s function.
To test whether SPR inhibition alleviates mechanical allodynia
in a fully established neuropathic pain state, we administered
SPRi3 to mice at 2, 3, or 4 weeks after the start of the SNI model
and after 6 weeks in the CCI model. Relative treatment efficacy
remained the same at each time point tested in bothmodels (Fig-
ure 6A; Figure S6A), indicating that BH4 production continues to
contribute to neuropathic pain at these later time points. Single
administration of SPRi3 produced no effect on motor coordina-
tion (Figure 6B), voluntary motor activity (Figure S6B), the hole-1400 Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc.board test (a paradigm sensitive to dopaminergic defects; Fig-
ure 6C; Figure S6C), or the tail suspension test (sensitive to
serotonin defects; Figure S6D). Acute administration of SPRi3
reduced plasma BH4 levels without affecting systolic blood
pressure and heart rate (Figure 6D; Figures S6E–S6H). When in-
jected repeatedly (two injections per day for 3 days), SPRi3 pro-
duced similar antiallodynic effects after the first and last injec-
tions (Figure 6E), indicating no tolerance. Under this dosage
regime the mice displayed no obvious adverse effects (no
change in appearance, weight, or general activity), and explora-
tion behaviors assessed by the holeboard test were not altered
(Figure 6F). In addition, serotonin and dopamine levels remained
unchanged in the striatum and hippocampus (Figure 6G; Fig-
ure S6I). Although SPR activity was reduced in the liver
(Figure 6H), as reflected by an increase in sepiapterin levels
(Figure 6I), phenylalanine plasma levels were not changed
throughout the treatment period (Figure 6J), showing that suffi-
cient levels of BH4 were maintained, despite the SPR inhibition,
to metabolize phenylalanine. The difference in sepiapterin levels
in plasma produced by an effective analgesic dose of SPRi3
(300 mg/kg) and an ineffective one (100 mg/kg) was sufficient
that this could be used as a biomarker of efficacy (Figure 6K).
The expression of Gch1 in and effects of SPRi3 on macro-
phage function, as well as the activity of SSZ in rheumatoid
arthritis (O’Dell et al., 2013), led us to assess whether SPRi3
could reduce inflammatory pain hypersensitivity, where these
cells play an important role (Marchand et al., 2005). Using
Gch1-eGFP mice, we found that intraplantar injection of
complete Freund’s adjuvant (CFA; 20 mg) caused infiltration
of macrophages within the paw, many of which expressed
Gch1 (Figure 7A). SPRi3 (300 mg/kg i.p.) significantly attenuated
for 1 hr the thermal hyperalgesia produced by intraplantar
CFA 1 day before (Figure 7B; Figure S7A) without affecting
mechanical allodynia (Figure S7B), and this was associated
with a decrease in BH4 levels in the inflamed paw (Figure 7C).
The development of thermal hyperalgesia after intraplantar
injection of CFA was not significantly affected in sensory
neuron-specific Gch1 KO mice (Figure 7D), suggesting that
BH4 produced by immune cells contributed to pain hypersensi-
tivity in this model.
We next administered CFA (20 mg) to the knee joint as a model
of rheumatoid arthritis. SPRi3 injection (300 mg/kg i.p.) signifi-
cantly improved weight-bearing defects for at least 1 hr when
administered 2, 3, and 4 days after CFA injection, but not on
day 1 (Figure 7E). Interestingly, under this daily SPRi3 injection
regime, knee thickness (a measure of inflammatory swelling)
resolved faster than in vehicle-injected animals (Figure 7F), sug-
gesting an anti-inflammatory action of the treatment. In support
of this, a preemptive paradigm where SPRi3 was first adminis-
tered 1 hr before CFA partially prevented the full establishment
of knee thickness and pain hypersensitivity the next day (Fig-
ure 7G; Figure S7C).
Systemic administration of an SPR inhibitor reduces BH4
production following peripheral nerve damage and inflammation,
and this alleviates pain-like hypersensitivity in mice through
effects on sensory neurons andmacrophages without tolerance,
noticeable side effects, or disturbances in BH4-dependent




Figure 5. SPR Inhibition Reduces BH4
Levels and Neuropathic Pain Hypersensi-
tivity
(A) Dose-dependent effects of i.p. injections of
SPRi3 on mechanical hypersensitivity in mice
7 days post SNI (left; n = 12–14) or 21 days after
CCI (right; n = 7–8).
(B and C) One hour after administration of SPRi3,
the compound was detected in SN (B) and
DRG (C), SPR activity was reduced, sepiapterin
levels increased, and BH4 levels were reduced
(n = 8–10).
(D) Antiallodynic effects of SPRi3 in Advillin-Gch1
KO mice 7 days post SNI (n = 8–10).
(E) SPRi3 (50 mM) reduces nitrite production in
purified peritoneal macrophages activated by LPS
(5 mg/ml) or LPS+ATP (1 mM).
Mean ± SEM. *p < 0.05; two-way ANOVA followed
by Bonferroni’s post hoc test (A and D). For [SPRi3]
and [sepiapterin], one-tailed Mann-Whitney test;
for SPR activity and BH4 levels, two-tailed un-
paired Student’s t test. Ø: not detected. See also
Figure S5.
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Figure 6. SPR Inhibition Reduces Established Neuropathic Pain
Signs without Side Effects
(A) Antiallodynic effects of SPRi3 in SNI mice 14, 21, and 28 days postsurgery
(left; n = 7–9) or 6 weeks after CCI (right; n = 7–8).
(B and C) SPRi3 1 hr after injection does not impact rotarod performance (B) or
exploration behaviors (C).
(D) SPRi3 does not affect systolic blood pressure 3 and 24 hr postinjection but
reduces BH4 plasma levels (n = 8–10).
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We designed an approach to ‘‘reverse engineer’’ human genetic
studies that have revealed an association between decreases in
BH4 synthesis and reduced neuropathic (Costigan et al., 2012;
Latremoliere and Costigan, 2011) and sickle cell disease pain
(Belfer et al., 2014) into mechanistic analyses in mouse models.
Animalmodels are critical to understand how,when, andwhere a
pathway may drive a disease process and to assess therapeutic
opportunities from inhibiting this pathway as well as liabilities
that may occur from such inhibition. We used tissue-specific
transgenic mice to formally demonstrate that BH4 modulates
pain sensitivity in somatosensory neurons. We found that BH4
overproduction leads to an NO-mediated heightened heat
pain sensitivity in uninjured mice, whereas preventing BH4 pro-
duction only in sensory neurons significantly attenuates the
development of nerve injury-induced mechanical hypersensitiv-
ity. The ability to reduce symptoms once they are fully estab-
lished is an essential prerequisite for any potential therapeutic
applications of a novel target pathway. We therefore generated
inducible sensory neuron-specific Gch1 KO mice to show
that blocking BH4 production is sufficient to partially reverse
established hypersensitivity, indicating that BH4 is involved in
maintaining the pain phenotype and, as a consequence, that
targeting this pathway in injured peripheral neurons may have
therapeutic utility.
In humans, the link between BH4 and pain was discovered
through identification of a haplotype allele of GCH1 that is both
associated with reduced pain and decreased transcription of
the GCH1 gene and BH4 production following cellular stress
(Tegeder et al., 2006) but without any of the major CNS, cardio-
vascular system (CVS), or metabolic effects found in patients
with loss-of-function mutations in BH4 synthetic enzymes.
These cause decreases in global BH4 levels below that required
to maintain adequate NO and aromatic amine synthesis, as well
as associated developmental defects (Bonafe´ et al., 2001; Doug-
las et al., 2015; Takazawa et al., 2008). The challenge then is how
to reduce elevated BH4 in target tissues, such as sensory neu-
rons and immune cells, without affecting excessively basal
levels in the brain, endothelial cells, and liver. Because GCH1
is an obligate enzyme in the de novo synthetic pathway, its(E) Mechanical pain thresholds in SNI mice after the first single i.p. adminis-
tration of SPRi3 (300 mg/kg) and after the last injection of a 3-day regime of
bidaily administration at 300 mg/kg (n = 8–9).
(F) Exploration behavior 30 min after the last injection of a 3-day regime of
bidaily injections of SPRi3.
(G) Amine levels and the ratio with their metabolites in the striatum 1 hr after the
last injection of the 3-day regime (n = 7–9). DA, dopamine; HIAA, 5-hydrox-
yindoleacetic acid; HVA, homovanillic acid.
(H and I) Sepiapterin reductase activity in liver 1 hr after SPRi3 (H) and se-
piapterin levels (I) (n = 4).
(J) Plasma phenylalanine levels 1 hr after vehicle, acute SPRi3 (300mg/kg i.p.),
and last injection of a 5-day regime of bidaily injections of SPRi3.
(K) Plasma sepiapterin level 1 hr after a non-pain-relieving dose of SPRi3
(100 mg/kg) and of a pain-relieving dose (300 mg/kg).
Mean ± SEM. *p < 0.05; two-way ANOVA followed by Bonferroni’s post hoc
test (A and E); one-tailed Mann-Whitney test (H and I); two-tailed unpaired
Student’s t test otherwise. Ø: not detected. See also Figure S6.
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Figure 7. SPR Inhibition Reduces BH4
Levels and Inflammatory Pain Hypersensi-
tivity
(A) Costaining of eGFPwith CD68 in paw skin 1 day
after intraplantar injection of CFA. The scale bar
represents 50 mm.
(B) Effects of SPRi3 on radiant heat latencies 1 day
after intraplantar injection of CFA (n = 8).
(C) Effects of SPRi3 on BH4 levels in plantar skin
after CFA.
(D) Radiant heat withdrawal latencies in Brn3a-
Gch1 KO mice before and 1 day after intraplantar
CFA (n = 5–6).
(E) Effects of SPRi3 on dynamic weight bearing
(DWB) 1, 2, 3, and 4 days after CFA injection
(n = 5–9). SPRi3 was administered on day 1, 2, 3,
and 4 after CFA injection, and DWB assessment
was performed 1 hr later. BL, baseline.
(F) Effects of SPRi3 treatment on knee thickness
caused by CFA injection into the joint. Each arrow
represents an injection. AUC, area under the curve.
(G) Effects of a preemptive treatment with SPRi3
DWB before and 1 day after CFA injection (n = 9).
Black: vehicle, yellow: SPRi3.
Mean ± SEM. *p < 0.05; two-way ANOVA followed
by Bonferroni’s post hoc test (B and E–G); one-
way ANOVA followed by Tukey’s post hoc test (C).
See also Figure S7.inhibition would cumulatively reduce BH4 levels as metabolites
in the salvage and recycling pathways were used up. We there-
fore targeted another enzyme in the de novo BH4 synthesis
pathway, SPR, downstream of GCH1. Although this enzyme
shows little transcriptional change after nerve injury and so far
has no described polymorphisms associated with altered pain
sensitivity, we hypothesized that it may represent amore reason-
able target to modulate BH4 production to produce pain relief
than GCH1. We hypothesized that systemic SPR blockade
would reduce nerve injury-induced BH4 overproduction without
fully blocking BH4 production in normal tissue, because
SPR’s substrate 6-pyruvoyl-tetrahydropterin can be converted
into BH4 through the salvage pathway, including metabolism
of sepiapterin, whose level we predicted would increase with
SPR inhibition. In human SPR loss-of-function mutations,
several cell types in peripheral tissues show such a diversion
of BH4 synthesis, and although these alternate synthesis routes
are less effective than the de novo synthesis pathway, they allow
sufficient BH4 production for maintaining baseline activity of
enzymes requiring this cofactor (Bonafe´ et al., 2001; Hirakawa
et al., 2009). Supporting such rescue of BH4 synthesis via these
pathways, we found that, although systemic administration of an
SPR inhibitor reduced BH4 levels in the DRG and injured nerve
sufficiently to reduce nerve injury-induced hypersensitivity, it
produced none of the side effects expected from global BH4
deficiency (Tho¨ny and Blau, 2006). Cardiovascular and behav-
ioral parameters particularly sensitive to NO, 5-hydroxytrypta-
mine (5-HT), or dopamine deficit were not altered and brain
amine levels remained unchanged after acute or repeated
administration of the SPR inhibitor. Furthermore, SPR inhibition
in the liver was not associated with increased phenylalanine
levels, indicating that sufficient BH4 levels were present in thistissue to allow phenylalanine hydroxylase function. These results
are in linewith the safety profile of sulfasalazine in patients, which
produces very few CNS, CVS, or metabolic side effects, even
when administered chronically at high doses (Costigan et al.,
2012). The pharmacological blockade of SPR maintained the
same relative efficacy for alleviating nerve injury-induced hyper-
sensitivity when tested at multiple times after injury, suggesting
that repeated treatment with an SPR inhibitor is possible without
pharmacological tolerance.
The degree of pain relief produced after systemic inhibition of
SPR was greater than that achieved after a Gch1 knockout
restricted to sensory neurons, which we interpret as indicating
that additional cell types produce BH4 after peripheral nerve
injury to generate pain and these are inhibited by SPR inhibitor
treatment. We found an infiltration of Gch1-expressing macro-
phages into the damaged nerve, and this represents a novel
and unsuspected source for BH4 production after peripheral
nerve injury and for participation in the generation of neuropathic
pain. Macrophages infiltrating the damaged nerve could pro-
duce several BH4-dependent molecules that might potentially
sensitize nociceptor fibers and contribute to neuropathic pain
hypersensitivity. One such factor is NO (Gorren and Mayer,
2002), and indeed we find that SPR inhibition in vitro blocked
NO production in macrophages. We found evidence for a contri-
bution of NO to the heat pain hypersensitivity resulting from
high constitutive BH4 levels in sensory neurons, but BH4 can
also produce a non-NO-mediated sensitization of nociceptors
(Nasser et al., 2015), indicating that this cofactor may modify
pain via diverse mechanisms in different pathological circum-
stances. For example, serotonin, whose synthesis is dependent
on BH4 (Friedman et al., 1972), sensitizes nociceptors through
the activation of 5-HT2A (Okamoto et al., 2002) and 5-HT3Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc. 1403
receptors (Kayser et al., 2007). Lowering production of 5-HT in
peripheral tissues by reducing BH4 could also participate in
reducing pain hypersensitivity.
Because NOS1 (neurons) and NOS2 (macrophages) have a
cumulative effect on pain hypersensitivity (Guan et al., 2007;
Kuboyama et al., 2011), it is possible that systemic inhibition
of SPR alleviates mechanical allodynia by decreasing activity
in both these enzymes in the two cell types, and the dual action
of the SPR inhibitor on neurons and immune cells may explain
its broad efficacy profile for neuropathic and inflammatory pain.
BH4 is involved in other aspects of macrophage function during
inflammation, such as redox and antioxidant reactions (McNeill
et al., 2015) and in regulation of their lipidome (Watschinger
et al., 2015), so that reducing BH4 may produce multiple anti-
inflammatory effects. Supporting a proinflammatory involve-
ment of BH4, we found that SPR inhibition in vivo reduced
inflammatory swelling and pain hypersensitivity in two inflam-
matory pain models, each with strong involvement of macro-
phages (Marchand et al., 2005). These results are in agreement
with clinical data reporting significant reductions in both pain
and inflammation in rheumatoid arthritis and inflammatory
bowel disease patients treated with sulfasalazine (Costigan
et al., 2012). Macrophages play an important role in both rheu-
matoid arthritis (Kinne et al., 2007; Li et al., 2012) and inflamma-
tory bowel disease (Heinsbroek and Gordon, 2009), and it is
possible, therefore, that BH4 production in these cells contrib-
utes to the disease.
Current medications for neuropathic pain show relative effi-
cacy in less than 50% of patients and cause disturbing side
effects in many (Finnerup et al., 2005, 2010). One reason for
this is the lack of quantifiable ways to titer doses for treatment
efficacy versus side effects. Our results show that sepiapterin
levels represent a reliable surrogate endpoint to quantify SPR
inhibition both in vitro and in vivo. We found a clear separation
between plasma sepiapterin levels in mice treated with a subop-
timal dose of SPR inhibitor and those treated with an effective
antiallodynic dose without detectable adverse effects. It is
conceivable that higher sepiapterin levels, indicating a greater
degree of SPR inhibition, could also define a side-effect window,
such as after high-dose prescriptions of sulfa-compound SPR
inhibitors (Haruki et al., 2013). Because this metabolite is chem-
ically stable, easily measured in plasma, and accumulates
only when SPR is inhibited, this confers a high signal-to-noise
ratio and specificity—critical properties for a biomarker (Wagner
et al., 2007).
In conclusion, our data illustrate how one can utilize human
genetics to discover a pathway involved in a disease and then
through preclinical mechanistic studies identify and target the
most suitable member of that pathway for drug development,
even if it was not the primary point of cascade detection.
Reducing BH4 production via SPR inhibition could represent a
viable approach for normalizing neuropathic and inflammatory
pain hypersensitivity, one that uniquely acts both on injured sen-
sory neurons and activated macrophages, and where adverse
effects may be limited by a salvage pathway that prevents
excessive reduction of the essential cofactor by diversion of
SPR’s substrate to low-level BH4 synthesis by alternative
pathways.1404 Neuron 86, 1393–1406, June 17, 2015 ª2015 Elsevier Inc.EXPERIMENTAL PROCEDURES
Genetic Gain- and Loss-of-Function Strategies
Mice expressing eGFP under the Gch1 promoter were used to label cells that
upregulateGch1 after SNI or CFA injection.Mice with aCre-dependentGCH1-
HA overexpression cassette produced BH4 overproduction, and Gch1 floxed
mice prevented BH4 production. For both gain- and loss-of-function experi-
ments, we bredGCH1-HA andGch1 floxed mice with sensory neuron-specific
Advillin-Cre, Na(v)1.8Tg-Cre, or the inducible Brn3a-CreER
T2 animals. All ani-
mal procedures were approved by the Boston Children’s Hospital Animal
Care and Use Committee.
Behavioral Assessments and Chronic Pain Models
Behavioral experiments were done blind to genotype or treatment. High-
threshold mechanical sensitivity was assessed by calibrated forceps, heat
sensitivity by radiant andcontact heat latencies, chemical nocifensive responses
by intraplantar injection of capsaicin, and thermal detection by thermal gradient.
For peripheral nerve injury, mice underwent SNI (Decosterd and Woolf,
2000) or CCI (Bennett and Xie, 1988). For inflammatory pain,mice received intra-
plantar or intraknee injection of CFA. In chronic models, mechanical allodynia
thresholds were determined using von Frey filaments, cold allodynia by acetone
evaporation, and movement-associated pain signs by dynamic weight bearing.
Biopterin/Sepiapterin/SPRi3 Concentrations
BH4, BH2, and biopterin samples were injected onto an isocratic HPLC sys-
tem and quantified using sequential electrochemical (Coulochem III; ESA)
and fluorescence detection (excitation 350 nm, emission 450 nm) (JASCO).
Sepiapterin concentrations were determined by liquid chromatography
coupled to electrospray ionization tandem mass spectrometry.
Statistical Analysis
Results are expressed as mean ± SEM unless specified otherwise. Details of
statistical assessment are in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2015.05.033.
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